The cardiovascular risk factor, soluble CD40 ligand (CD154), but not Soluble CD40 is lowered by ultra-endurance exercise in athletes

British Journal of Sports Medicine

Volumn 45, Issue 1, 2011, Pages 42-45

  Geertsema, Liesel ^a   Lucas, Samuel J E ^b   Cotter, James D ^b   Hock, Barry ^c   McKenzie, Judy ^c   Fernyhough, Liam J ^b  

^a Australasian College of Sports Medicine   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CANTERBURY DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND;

ADULT; ARTICLE; BICYCLE; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; EXERCISE; HUMAN; JOGGING; MALE; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SPORT;

ADULT; BICYCLING; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CD40 LIGAND; CROSS-OVER STUDIES; EXERCISE; HUMANS; JOGGING; MALE; RISK FACTORS; SPORTS;

EID: 78650863251     PISSN: 03063674     EISSN: 14730480     Source Type: Journal    
DOI: 10.1136/bjsm.2008.051896     Document Type: Article

References (20)

1. Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003;108:1049-52.
2. Schönbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266-8.
3. Paffenbarger RS Jr, Hyde RT, Wing AL, et al. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993;328:538-45.
4. Sandvik L, Erikssen J, Thaulow E, et al. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med 1993;328:533-7.
5. Lee IM, Sesso HD, Paffenbarger RS Jr. Physical activity and coronary heart disease risk in men: does the duration of exercise episodes predict risk? Circulation 2000;102:981-6.
6. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005;98:1154-62.
7. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002;12:27-32.
8. Häkkinen T, Karkola K, Ylä-Herttuala S. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch 2000;437:396-405.
9. Melter M, Reinders ME, Sho M, et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 2000;96:3801-8.
10. Schönbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 2000;97:7458-63.
11. Kinlay S, Schwartz GG, Olsson AG, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004;110:386-91.
12. Santilli F, Davì G, Consoli A, et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 2006;47:391-7.
13. Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003;107:2664-9.
14. Astrand PO, Rodahl K. Textbook of Work Physiology: Physiological Bases of Exercise. 3rd edn. Singapore: McGraw-Hill Book, 1986.
15. Hock BD, McKenzie JL, Patton NW, et al. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer 2006;106:2148-57.
16. Frolov A, Hui DY. The modern art of atherosclerosis: a picture of colorful plants, cholesterol, and inflammation. Arterioscler Thromb Vasc Biol 2007;27:450-2.
17. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001;89:1092-103.
18. Mach F, Schönbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394:200-3.
19. Gilmore TD. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 1999;18:6842-4.
20. Thom J, Gilmore G, Yi Q, et al. Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J Thromb Haemost 2004;2:2067-9.